Spexis AG, NewAmsterdam Pharma, Molecure, and Cyclo Therapeutics: Key Updates

Spexis AG announces changes to its Executive Committee, with Hernan Levett leaving as Chief Financial Officer. Martin Jakobovic will succeed him as interim Chief Financial Officer. NewAmsterdam Pharma appoints Ian Somaiya as Chief Financial Officer. Molecure provides first half 2023 financial results and updates on its clinical trials. Cyclo Therapeutics, Inc. and Applied Molecular Transport Inc. enter into a merger agreement.